DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma
Patients with first or second recurrence of GBM will be treated with stereotactic injection of the oncolytic virus DNX-2440.
Glioblastoma|Glioblastoma, Adult
DRUG: DNX-2440 injection
Incidence of Treatment-Emergent Adverse Events after brain administration of DNX-2440., Incidence and severity of adverse effects will be collected and described, 8 weeks
Overall Survival at 12 months (OS12), rate of patients surviving at 12 months since injection, 12 months|Overall survival, Survival along the whole interval of follow-up, 25 months|Overall response rate (ORR), total of patients with Complete responses plus partial responses, 6 months
After inclusion in the trial, stereotactic biopsy will be performed. In the same surgery, the experimental agent will be injected also by stereotactic system, in a different part of the lesion, in a region considered viable tumor, using a cannula especially designed for virus injection.

Follow-up will include clinical visits and MRI No other treatment for the tumor will be used until progression is documented. iRANO criteria and volumetric measurement of the tumor will be used.

Any further treatment after progression will be at the criteria of the treating physician